Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-27
2008-05-27
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C548S467000, C548S470000
Reexamination Certificate
active
07378438
ABSTRACT:
The present invention relates to multifunctional β-agonist compounds comprising a reactive oxygen species scavenger group and a nitric oxide donor, and their use for the treatment of respiratory diseases involving airway obstruction, such as asthma and chronic bronchitis. The invention further relates to methods and devices for administering the compounds.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5277195 (1994-01-01), Williams
patent: 5320094 (1994-06-01), Laube et al.
patent: 5327883 (1994-07-01), Williams et al.
patent: 5364833 (1994-11-01), Kast et al.
patent: 5364838 (1994-11-01), Rubsamen
patent: 5404871 (1995-04-01), Goodman et al.
patent: 5419315 (1995-05-01), Rubsamen
patent: 5492112 (1996-02-01), Mecikalski et al.
patent: 5506203 (1996-04-01), Bäckström et al.
patent: 5518998 (1996-05-01), Bäckström et al.
patent: 5558085 (1996-09-01), Rubsamen et al.
patent: 5577497 (1996-11-01), Mecikalski et al.
patent: 5622166 (1997-04-01), Eisele et al.
patent: 5645051 (1997-07-01), Schultz et al.
patent: 5654007 (1997-08-01), Johnson et al.
patent: 5655523 (1997-08-01), Hodson et al.
patent: 5658878 (1997-08-01), Bäckström et al.
patent: 5661130 (1997-08-01), Meezan et al.
patent: 5672581 (1997-09-01), Rubsamen et al.
patent: 5700904 (1997-12-01), Baker et al.
patent: 5743250 (1998-04-01), Gonda et al.
patent: 5780014 (1998-07-01), Eljamal et al.
patent: 5821259 (1998-10-01), Theoharides
patent: 5824669 (1998-10-01), Garvey et al.
patent: 6060069 (2000-05-01), Hill et al.
patent: 6083993 (2000-07-01), Barberich et al.
patent: 6124319 (2000-09-01), MacCoss et al.
patent: RE37116 (2001-03-01), Garvey et al.
patent: 6232331 (2001-05-01), Sankaranarayanan
patent: 6238647 (2001-05-01), Akehurst et al.
patent: 6241969 (2001-06-01), Saidi et al.
patent: 6248895 (2001-06-01), Sankaranarayanan
patent: 6254882 (2001-07-01), Jerussi
patent: 6297762 (2001-10-01), Labitt
patent: 6299863 (2001-10-01), Aberg et al.
patent: 6335316 (2002-01-01), Hughes et al.
patent: 6369071 (2002-04-01), Haj-Yehia
patent: 6448267 (2002-09-01), Anggard et al.
patent: 6455542 (2002-09-01), Anggard et al.
patent: 6492405 (2002-12-01), Haj-Yehia
patent: 6642260 (2003-11-01), Haj-Yehia
patent: 6759430 (2004-07-01), Anggard et al.
patent: 2001/0041190 (2001-11-01), Ward et al.
patent: 2002/0006901 (2002-01-01), Iacono
patent: 2002/0034477 (2002-03-01), Edwards et al.
patent: 2004/0147598 (2004-07-01), Haj-Yehia
patent: 733202 (1997-10-01), None
patent: 2 349 385 (2000-11-01), None
patent: WO-95/24183 (1995-09-01), None
patent: WO-95/30641 (1995-11-01), None
patent: WO-96/32149 (1996-10-01), None
patent: WO-96/32946 (1996-10-01), None
patent: WO-96/39409 (1996-12-01), None
patent: WO-97/25984 (1997-07-01), None
patent: WO-97/31654 (1997-09-01), None
patent: WO-97/34871 (1997-09-01), None
patent: WO-98/33480 (1998-08-01), None
patent: WO-98/42661 (1998-10-01), None
patent: WO-98/55453 (1998-12-01), None
patent: WO-99/37616 (1999-07-01), None
patent: WO-99/40787 (1999-08-01), None
patent: WO-99/61018 (1999-12-01), None
patent: WO-99/61430 (1999-12-01), None
patent: WO-99/62509 (1999-12-01), None
patent: WO-99/66918 (1999-12-01), None
patent: WO-00/31060 (2000-06-01), None
patent: WO-00/35434 (2000-06-01), None
patent: WO-00/35434 (2000-06-01), None
patent: WO-00/53191 (2000-09-01), None
patent: WO-00/53191 (2000-09-01), None
patent: WO-00/67754 (2000-11-01), None
patent: WO-01/32202 (2001-05-01), None
patent: WO-03/088961 (2003-10-01), None
Johansson et al., “b2-Adrenoceptor selectivity in four series of b-adrenoceptor agonists,” European Journal of Pharmacology, vol. 130(1-2), pp. 97-103 (1986).
Johansson et al., “β2-Adrenoceptor selectivity in four series of β-adrenoceptor agonists,” European Journal of Pharmacology, vol. 130(1-2), pp. 97-103 (1986).
Anonymous (Nov. 3, 1990). “Editorials: β2 Agonists in Asthma: Relief, Prevention, Morbidity,”Lancet336(8723):1411-1412.
Boushey, H.A. (1998). “Bronchodilators & Other Agents Used in Asthma,” Chapter 20In Basic&Clinical PharmacologySeventh Edition, Katzung, B.G. ed. Appleton and Lange: Stamford, CT pp. 325-342.
Burrows, B. et al. (Feb. 20, 1992). “The β-Agonist Dilemma,”The New England Journal of Medicine326(8):560-561.
Costello, J.F. ed. (1997).Sympathomimetic Enantiomers in the Treatment of AsthmaThe Parthenon Publishing Group, Inc.: London. (Table of Contents Only.).
Cotran, R.S. et al. (1989). “The Respiratory System” Chapter 16In Robbins Pathologic Basis of DiseaseFourth Edition, W.B. Saunders Co.: Philadelphia, PA pp. 755-797.
Haahtela, T. et al. (Aug. 8, 1991). “Comparison of a B2-Agonist, Terbutaline, With an Inhaled Corticosteroid, Budesonide, in Newly Detected Asthma,”The New England Journal of Medicine325(6):388-392.
Haj-Yehia, A. et al. (Jul./Aug. 2000). “Development of 3-Nitratomethyl-PROXYL (NMP): A Novel, Bifunctional Superoxide Dismutase-Mimic-Nitric Oxide-Donor,”Drug Development Research50(3/4):528-536.
Hansel, T. et al. ed. (2001).New Drugs for Asthma, Allergy and COPDKarger: London, vol. 31, pp. v-vii (Table of Contents Only.).
Hett, R. et al. (1994). “Enantioselective Synthesis of Salmeterol via Asymmetric Borane Reduction,”Tetrahedron Letters35(50):9375-9378.
Hett, R. et al. (1997). “Enantio- and Diastereoselective Synthesis of all Four Stereoisomers of Formoterol,”Tetrahedron Letters38(7):1125-1128.
Hoffman, B.B. (1998). “Adrenoceptor-Activating & Other Sympathomimetic Drugs,” Chapter 9In Basic&Clinical PharmacologySeventh Edition, Katzung, B.G. ed. Appleton and Lange: Stamford, CT pp. 118-151.
Jansen, A. et al. (1992). “The Relaxant Properties in Guinea Pig Airways of S-Nitrosothiols,”J. Pharmacol. Exptl. Therapeutics261(1):154-160.
Kaminsky, D.A. et al. (Oct. 1999). “Nitrotyrosine Formation in the Airways and Lung Parenchyma of Patients with Asthma,”J. Allergy Clin. Immunol. 104(4/1):747-754.
Murray, J.F. et al. eds. (Oct.-Nov. 1979).American Review of Respiratory Disease120(4/5) (Table of Contents Only.).
Rees, J. (May 18, 1991). “B2 Agonists and Asthma,”British Medical Journal302(6786):1166-1167.
Robak, J. et al. (1993). “Nitric Oxide Donors as Generators and Scavengers of Superoxide Anions,”Pol. J. Pharmacol. 45(1):51-58.
Robak, J. et al. (Dec. 20, 1993). “Nitric Oxide Donors as Generators and Scavengers of Superoxide Anions,”Chemical Abstracts25:71 Abstract No. 119:262465b.
Shiraishi, M. et al. (Oct. 14, 1996). “Drugs for Improvement of Lipid Metabolism,”Chemical Abstracts125(16):649 Abstract No. 125:204523g.
Spitzer, W.O et al. (Feb. 20, 1992). “The Use of β-Agonists and the Risk of Death and Near Death From Asthma,”The New England Journal of Medicine326(8):501-506.
Svedmyr, N. et al. (1990). “The Current Place of β2-Agonists in the Management of Asthma,”Lung168(Supp):105-110.
Tamaoki, J. et al. (Jun. 1995). “Role of NO Generation in β-Adrenoceptor-Mediated Stimulation of Rabbit Airway Ciliary Motility,”Am. J. Physiol. 268(6):C1342-C1346.
Thompson, R.F. et al. (Jul.-Aug. 1985). “Hypersensitivity Vasculitis Associated With Streptokinase,”Clin. Pharm. 4(4):383-386.
Wagner, A.F. et al. (Oct. 5, 1956). “Properties and Derivatives of α-Lipoic Acid,”Journal of the American Chemical Society78:5079-5081.
Wolf, E.W. et al. (1998). “Reversal of Cerebral Vasospasm Using an Intrathecally Administered Nitric Oxide Donor,”J. Neurosurg. 89(2):279-288.
Anderson Rebecca L
McCarthy Kevin D.
Nolan Jason M
Roach Brown McCarthy & Gruber P.C.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Beta-agonist compounds comprising nitric oxide donor groups... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-agonist compounds comprising nitric oxide donor groups..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-agonist compounds comprising nitric oxide donor groups... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779581